180 related articles for article (PubMed ID: 2540748)
1. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin K; Hong T; Levy JV
Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
5. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series.
Weber KH; Heuer H
Int Arch Allergy Appl Immunol; 1989; 88(1-2):82-7. PubMed ID: 2540098
[TBL] [Abstract][Full Text] [Related]
7. The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes.
Svetlov SI; Barton JM; Olson MS
Life Sci; 1996; 58(5):PL 81-6. PubMed ID: 8594301
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
9. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
Ammit AJ; O'Neill C
Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
[TBL] [Abstract][Full Text] [Related]
10. The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF).
Griffin KJ; Levy JV
Thromb Res; 1988 Jul; 51(2):219-23. PubMed ID: 3187959
[No Abstract] [Full Text] [Related]
11. Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. Correlation between receptor binding and function.
Dent G; Ukena D; Chanez P; Sybrecht G; Barnes P
FEBS Lett; 1989 Feb; 244(2):365-8. PubMed ID: 2537761
[TBL] [Abstract][Full Text] [Related]
12. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
[TBL] [Abstract][Full Text] [Related]
13. Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity.
Casals-Stenzel J; Weber KH
Br J Pharmacol; 1987 Jan; 90(1):139-46. PubMed ID: 2880622
[TBL] [Abstract][Full Text] [Related]
14. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
Stewart AG; Dusting GJ
Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
[TBL] [Abstract][Full Text] [Related]
15. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
Silva CL; Cruz HN; Violante FA; Cordeiro RS; Martins MA; Noël F
Biochem Pharmacol; 1996 Jan; 51(2):193-6. PubMed ID: 8615889
[TBL] [Abstract][Full Text] [Related]
16. Effects of antiplatelet agents on platelet aggregation induced by platelet--activating factor (PAF) in human whole blood.
Chan WP; Levy JV
Prostaglandins; 1991 Oct; 42(4):337-42. PubMed ID: 1665568
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
19. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
Foster AP; Lees P; Andrews MJ; Cunningham FM
Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
